Akero Therapeutics

Yahoo Finance • 4 days ago

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet med... Full story

Yahoo Finance • 10 days ago

Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism

Akero Therapeutics Inc (NASDAQ:AKRO [https://www.chartmill.com/stock/quote/AKRO]) reported its second-quarter 2025 financial results, with a net loss of $70.5 million, or $0.86 per share, compared to a net loss of $56.0 million, or $0.81 p... Full story

Yahoo Finance • 10 days ago

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (... Full story

Yahoo Finance • 11 days ago

Akero therapeutics CSO Rolph sells $616,299 in stock

Akero Therapeutics (NASDAQ:AKRO) Chief Scientific Officer Timothy Rolph sold 12,500 shares of common stock on August 5, 2025, for a total of $616,299. The sales were executed in two transactions at prices ranging from $49.065 to $49.494. T... Full story

Yahoo Finance • 14 days ago

Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH potential

Investing.com - TD Cowen initiated coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and a $76.00 price target on Monday. The company, currently valued at $3.91 billion, has seen its stock surge over 92% in the past year. The... Full story

Yahoo Finance • 14 days ago

Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH treatment potential

Investing.com - TD Cowen has initiated coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and a price target of $76.00. According to InvestingPro data, this aligns with the strong analyst consensus, with targets ranging from $6... Full story

Yahoo Finance • 21 days ago

Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's strong launch fuels stock outlook

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.57 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra, which has shown promising results in treating nonalcoholic... Full story

Yahoo Finance • last month

Akero Therapeutics CEO Cheng sells $1.5m in stock

Akero Therapeutics (NASDAQ:AKRO), a $4.1 billion market cap biotech company whose shares have surged over 107% in the past six months, saw its President and CEO Andrew Cheng sell 30,000 shares of common stock on July 10, 2025, in two separ... Full story

Yahoo Finance • last month

Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's strong launch propels stock outlook

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biotechnology sector with its flagship drug Rezdiffra, a treatment for nonalcoholic steatohepatitis (NASH). With a market capitalization of $6.6 billion and accordin... Full story

Yahoo Finance • 2 months ago

Akero therapeutics CSO Rolph sells $61,914 in shares

Akero Therapeutics, Inc. (NASDAQ:AKRO), a $4.35 billion market cap biotech company whose stock has surged 133% over the past year, reported that Chief Scientific Officer Timothy Rolph sold 1,129 shares of common stock on June 18, 2025, acc... Full story

Yahoo Finance • 2 months ago

Akero Therapeutics SVP Lamy sells $47k in shares

Akero Therapeutics (NASDAQ:AKRO) Senior Vice President, Commercial Strategy, Patrick Lamy, sold 875 shares of common stock on June 20, 2025, at a price of $54.59, according to a Form 4 filing with the Securities and Exchange Commission. Th... Full story

Yahoo Finance • 2 months ago

Akero Therapeutics (AKRO) CEO Andrew Cheng sells $363k in stock

Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 6,620 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted-ave... Full story

Yahoo Finance • 2 months ago

Akero Therapeutics CTO Gangloff sells $46,504 in stock

Akero Therapeutics (NASDAQ:AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504. The sale comes as the stock trades near it... Full story

Yahoo Finance • 2 months ago

Akero Therapeutics (AKRO) CFO White sells $89k in stock

William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 1,634 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at... Full story

Yahoo Finance • 2 months ago

Akero therapeutics chief development officer Yale sells $89k in stock

Akero Therapeutics (NASDAQ:AKRO) Chief Development Officer Yale Catriona sold 1,633 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The $4.35 billion market cap company has... Full story

Yahoo Finance • 2 months ago

Jefferies sees promising M&A targets in biotech sector amid stabilizing market

Jefferies has identified several biotechnology companies as promising merger and acquisition targets, highlighting firms with de-risked or commercial-stage assets that could generate significant sales. In a recent research note, the firm s... Full story

Yahoo Finance • 3 months ago

Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today

We recently published a list of These 10 Firms Just Beat the Market Today. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other stocks that skyrocketed today. Ten companies boas... Full story

Yahoo Finance • 3 months ago

Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing healthcare stocks to buy now... Full story

Yahoo Finance • 3 months ago

Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025

Die Analyse der Ergebnisse zu EFX mit KI-basierter digitaler Pathologie unterstreicht den potenziellen Wert bei der Bewertung des histopathologischen Ansprechens Die Daten tragen dazu bei, dass die antifibrotische Wirkung von EFX bei Pati... Full story

Yahoo Finance • 3 months ago

Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibrose ohne Verschlechterung der MASH

SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten mit schwerwiegenden Stoffwechselkrankh... Full story